Anti-RSV Study in Chinese Patients (ASCENT)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-29

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomised, double-blind, placebo-controlled, multicentre, phase 2 study to evaluate the efficacy, safety and tolerability of orally administered AK0529 in Chinese adults with RSV infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of AK0529 in Adults Patients Hospitalized With RSV Infection

NCT06942299

Respiratory Syncytial Virus Infections

COMPLETED PHASE2

A Study of AK0529 in Chinese Infants Hospitalized With RSV

NCT04231968

Respiratory Syncytial Virus Infections

COMPLETED PHASE3

A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants

NCT06775405

Respiratory Synctial Virus Infections

RECRUITING PHASE3

Safety, Tolerability and PK Study of AK0529 in Healthy Human

NCT02297594

Respiratory Syncytial Virus Infections

COMPLETED PHASE1

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

NCT07220109

Respiratory Syncytial Virus Infections

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomised, double-blind, placebo-controlled, multicentre, phase 2 study in Chinese adult outpatients with RSV infection. Approximately 160 eligible patients who have been recently diagnosed with RSV infection are planned to be enrolled into the study. Symptom scores of patients before and after treatment will be evaluated. Meanwhile, nasopharyngeal samples and blood samples will be collected for virological and pharmacokinetics evaluations. The evaluation of the safety and tolerability will include AE/SAE, vital signs, physical examination, laboratory examination and 12-lead ECGs. The total study duration for each patient will be 20 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Syncytial Virus Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

100mg AK0529 Arm

Patients randomised into this arm will be orally administered with 100mg AK0529 q.d. for five days.

Group Type EXPERIMENTAL

AK0529

Intervention Type DRUG

AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.

200mg AK0529 Arm

Patients randomised into this arm will be orally administered with 200mg AK0529 q.d. for five days.

Group Type EXPERIMENTAL

AK0529

Intervention Type DRUG

AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.

300mg AK0529 Arm

Patients randomised into this arm will be orally administered with 300mg AK0529 q.d. for five days.

Group Type EXPERIMENTAL

AK0529

Intervention Type DRUG

AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.

Placebo Arm

Patients randomised into this arm will be orally administered with placebo q.d. for five days.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

The placebo is made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed of microcrystaline cellulose pellet.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AK0529

AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.

Intervention Type DRUG

Placebo

The placebo is made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed of microcrystaline cellulose pellet.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ziresovir

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 - 75 years, inclusive.
* Confirmed with RSV infection by rapid diagnostic testing.
* New onset with documentation of the following symptoms within 72 hours prior to the start of screening: Respiratory symptoms: runny nose, stuffy nose, sneezing, sore throat, earache, cough, shortness of breath; Systemic symptoms: headache, fatigue / lethargy, fever, and muscle and / or joint ache. The patient must have four symptoms of above, and at least one of these must be respiratory symptom in nature.
* Able and willing to provide written informed consent and to comply with the study protocol.

Exclusion Criteria

* The patient has taken, is taking or needs to take any antiviral medication (e.g. ribavirin, Chinese medicine or herbs with effects of treating respiratory tract infection) within the 72 hours prior to screening.
* Awareness of concomitant infections of respiratory viruses (eg, influenza A, B), bacterial or fungal infections, including systemic bacterial or fungal infections within 7 days prior to screening or during the screening period.
* Patient frailty was evaluated as "Vulnerable" or worse according to the Clinical Frailty Scale with a score ≥ 4 at screening.
* Awareness of having positive results on HBsAg or HCV antibody or HIV (HIV 1 or HIV 2).
* Patient with active tuberculosis or is taking antituberculosis treatment.
* Patient with severe gastrointestinal disease which could impact drug absorption, eg, vomiting, malabsorption syndrome, or short bowel syndrome caused by necrotizing enterocolitis.
* Patient with any congenital heart disease, acute or chronic heart failure, ischemic heart disease, or congenital long QT syndrome, or any clinical manifestation resulting in QT interval prolongation.
* Patient with malignant tumor.
* Patient has received or is waiting for bone marrow, stem cell or solid organ transplantation.
* Patient with any immune-related disease to be treated within 12 months prior to screening.
* Patient with clinical laboratoy test values of ≥ 2x the upper limit of normal (ULN) for alanine aminotransferase or aspartate aminotransferase, or \>1x ULN for total bilirubin, or \>1.5xULN for serum creatinine.
* Patient with electrolyte disorders, eg, hypokalemia, hypocalcemia, or hypomagnesemia.
* Patient with history of drug or alcohol abuse within 12 months prior to screening ("alcohol abuse" definition is \>14 units per week: 1 unit = 10mL Alcohol, or 250mL of 4% beer, or 25 mL of 40% spirit, or 75 mL of 13% wine).
* Patient has allergy or hypersensitivity to study medication or its compositions.
* Female patient with positive pregnancy test result or is lactating.
* Patient with fertility refusing to use medically effective contraceptives during the study or within three months of the end of study.
* Patient participated in an investigational drug or device study within 60 days prior to screening.
* Patient who in the opinion of the investigator, is deemed as ineligible for the study, including patients who are with active psychiatric disease, or are taking psychiatric medication.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ark Clinical Trial

Role: STUDY_DIRECTOR

[email protected]

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beijing Ditan Hospital

Beijing, Beijing Municipality, China

Site Status RECRUITING